Stock market today: S&P 500 hits fresh record close on stronger economic growth
PALO ALTO, Calif. - Kalaris Therapeutics, Inc. (NASDAQ:KLRS), a biopharmaceutical company focused on retinal disease treatments, announced today the addition of Leone Patterson to its Board of Directors. Patterson will also serve as Chair of the Board’s Audit Committee.
Leone Patterson, currently the Executive Vice President, Chief Business Officer, and Chief Financial Officer of Zymeworks, brings extensive experience in biotech finance and operations to Kalaris. Her previous roles include Chief Financial and Business Officer at Tenaya Therapeutics and leadership positions at Adverum Biotechnologies, Diadexus, Transcept, Exelixis, Novartis, and Chiron. Patterson is also a board member at Nkarta, Inc.
David Hallal, Chairman of the Kalaris Board of Directors, expressed confidence in Patterson’s abilities, citing her strategic and operational capabilities as key assets for the company. Patterson herself acknowledged the potential of Kalaris’s lead asset and the opportunity to impact the treatment of retinal diseases.
Kalaris is currently advancing TH103, an investigational anti-VEGF therapy, through clinical trials for neovascular Age-related Macular Degeneration (nAMD) and plans to explore its application in other retinal diseases.
This press release includes forward-looking statements regarding the future operations and potential efficacy of TH103. These statements are subject to risks and uncertainties, and actual results may differ materially.
The information in this article is based on a press release statement from Kalaris Therapeutics, Inc.
In other recent news, AlloVir, Inc. has announced a merger with Kalaris Therapeutics, Inc., following shareholder approval. The merger is expected to close soon, pending customary closing conditions, and the combined entity will operate under the name Kalaris Therapeutics, Inc. Additionally, AlloVir has executed a reverse stock split at a 1-for-23 ratio, consolidating every twenty-three shares of its common stock into one share. This strategic move aims to adjust the trading price of AlloVir’s common stock, potentially enhancing its marketability and compliance with Nasdaq’s listing requirements. Shareholders holding fractional shares will receive a cash payment equivalent to the fractional share multiplied by the closing sales price. The reverse stock split is part of AlloVir’s broader strategy in anticipation of the merger with Kalaris. The company has filed relevant materials with the SEC regarding both the merger and the reverse stock split. Investors are encouraged to review these documents for detailed information.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.